| # | Title | Journal | Year | Citations |
|---|
| 1 | Systematic variation in gene expression patterns in human cancer cell lines | Nature Genetics | 2000 | 1,946 |
| 2 | Control of apoptosis by p53 | Oncogene | 2003 | 1,256 |
| 3 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study | Lancet Oncology, The | 2020 | 923 |
| 4 | Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy | Nature | 2004 | 898 |
| 5 | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Blood | 2010 | 680 |
| 6 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study | Lancet Oncology, The | 2019 | 611 |
| 7 | Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity | Blood | 2010 | 473 |
| 8 | Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment | | 2014 | 460 |
| 9 | Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis | Leukemia | 2016 | 393 |
| 10 | Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | Blood | 2013 | 383 |
| 11 | Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 | Journal of Immunology | 2010 | 381 |
| 12 | Targeting the checkpoint kinases: chemosensitization versus chemoprotection | Nature Reviews Cancer | 2004 | 356 |
| 13 | Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer | Cancer Cell | 2006 | 348 |
| 14 | Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial | Journal of Hematology and Oncology | 2017 | 302 |
| 15 | Recent Advances in the Discovery of Competitive Protein Tyrosine Phosphatase 1B Inhibitors for the Treatment of Diabetes, Obesity, and Cancer | Journal of Medicinal Chemistry | 2010 | 286 |
| 16 | The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy | Diabetes Care | 2010 | 281 |
| 17 | Cdk1/Erk2- and Plk1-Dependent Phosphorylation of a Centrosome Protein, Cep55, Is Required for Its Recruitment to Midbody and Cytokinesis | Developmental Cell | 2005 | 273 |
| 18 | Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia | Blood | 2012 | 263 |
| 19 | Genome-wide mapping with biallelic markers in Arabidopsis thaliana | Nature Genetics | 1999 | 260 |
| 20 | JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response | Cancer Discovery | 2015 | 252 |
| 21 | Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR | Oncotarget | 2014 | 248 |
| 22 | Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I | Haematologica | 2015 | 246 |
| 23 | First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies | Clinical Cancer Research | 2017 | 244 |
| 24 | Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors | Nature Reviews Cancer | 2006 | 239 |
| 25 | Cross-Talk between Activated Human NK Cells and CD4+ T Cells via OX40-OX40 Ligand Interactions | Journal of Immunology | 2004 | 238 |
| 26 | Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors | Molecular Cancer Therapeutics | 2010 | 236 |
| 27 | INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology | ACS Medicinal Chemistry Letters | 2017 | 235 |
| 28 | Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate | Annals of the Rheumatic Diseases | 2015 | 232 |
| 29 | Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial | Lancet Oncology, The | 2015 | 232 |
| 30 | Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model | Journal of Medicinal Chemistry | 2009 | 212 |
| 31 | Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses | Journal of Hematology and Oncology | 2017 | 210 |
| 32 | A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis | Haematologica | 2015 | 203 |
| 33 | A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3 | Clinical Cancer Research | 2011 | 201 |
| 34 | Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia | Blood | 2012 | 178 |
| 35 | Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial | Blood | 2020 | 176 |
| 36 | Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344 | Journal of Immunology | 2005 | 168 |
| 37 | Developing c-MET pathway inhibitors for cancer therapy: progress and challenges | Trends in Molecular Medicine | 2010 | 165 |
| 38 | A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea | Cancer | 2014 | 165 |
| 39 | SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth | IEEE Transactions on Medical Imaging | 2019 | 163 |
| 40 | Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells | Cancer Biology and Therapy | 2006 | 159 |
| 41 | Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis | Journal of the American Academy of Dermatology | 2012 | 158 |
| 42 | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis | Blood | 2015 | 151 |
| 43 | Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream | Journal of Allergy and Clinical Immunology | 2020 | 151 |
| 44 | Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies | Journal of the American Academy of Dermatology | 2021 | 151 |
| 45 | Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial | Lancet, The | 2020 | 148 |
| 46 | Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib | Cancer Discovery | 2021 | 144 |
| 47 | Enantioselective Synthesis of Janus Kinase Inhibitor INCB018424 via an Organocatalytic Aza-Michael Reaction | Organic Letters | 2009 | 143 |
| 48 | Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I | Haematologica | 2013 | 143 |
| 49 | Targeting the Janus Kinase Family in Autoimmune Skin Diseases | Frontiers in Immunology | 2019 | 141 |
| 50 | Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial | Haematologica | 2016 | 140 |
